Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling